Damora Therapeutics
DMRA
18 hedge funds and large institutions have $65.5M invested in Damora Therapeutics in 2025 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 6 closing their positions.
10,237% more capital invested
Capital invested by funds: $633K → $65.5M (+$64.8M)
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
56.6% more ownership
Funds ownership: 12.85% → 69.45% (+57%)
50% more funds holding
Funds holding: 12 → 18 (+6)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$4.97M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.15M |
| 3 |
JG
Jain Global
New York
|
+$2.1M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.89M |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$1.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$322K |
| 2 |
CCM
Connective Capital Management
Palo Alto,
California
|
-$100K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$91.6K |
| 4 |
Two Sigma Investments
New York
|
-$75.5K |
| 5 |
Renaissance Technologies
New York
|
-$56K |
DMRA Hedge Fund Activity: Q4 2025 in Review
18 of the 8,275 institutional investors tracked by Wall St. Rank reported a position in Damora Therapeutics (DMRA) for Q4 2025, worth a combined $65.5M — up 10,237% from $633K a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new DMRA positions and 6 closed out — a net gain of 6 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $4.97M. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $322K sold.
- 18 institutional investors held Damora Therapeutics (DMRA) as of Q4 2025, up from 12 in Q3 2025.
- Funds reported $65.5M of Damora Therapeutics stock for Q4 2025, up 10,237% quarter-over-quarter.
- 12 funds opened new Damora Therapeutics positions in Q4 2025 and 6 closed out, a net change of +6 holders.
- The largest Damora Therapeutics buyer in Q4 2025 was Ikarian Capital, an estimated $4.97M added.
- The largest Damora Therapeutics seller in Q4 2025 was Novo Holdings A/S, an estimated $322K sold.
Based on aggregated 13F filings for Q4 2025.